Browse the evidence

Genetic variants in GLP1R that increase weight loss efficacy are also associated with an increased risk of nausea and vomiting, suggesting a link between efficacy and side effects.

Research suggests that the same genetic factors that help you lose more weight with GLP-1 medications may also make you more prone to nausea and vomiting. This doesn't mean you must suffer, but it highlights why side effects vary so much between individuals. If you are struggling with severe side effects, it might be worth discussing with your doctor whether a different medication or dose adjustment could help, as your genetics might be driving both your response and your side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly, liraglutide 3.0 mg daily) cause modest bone mineral density (BMD) reduction and increase bone turnover markers (favoring resorption) in people living with obesity, mirroring the effects of calorie restriction.

If you are taking GLP-1 agonists like Wegovy or Saxenda for weight loss, expect a small decrease in bone density (around 2-3%) over a year, similar to losing weight through diet alone. This is not unique to the drug but to the weight loss itself. To protect your bones, prioritize resistance training and ensure you are getting enough calcium and Vitamin D. The benefit of weight loss generally outweighs this modest skeletal risk, but monitoring is advised.

Transitioning from dulaglutide to tirzepatide improves glycemic control (increased time in range, decreased mean glucose) without increasing hypoglycemia in patients with type 2 diabetes undergoing hemodialysis.

For patients with type 2 diabetes on hemodialysis who are not achieving good blood sugar control on dulaglutide, switching to tirzepatide (2.5 mg weekly) can significantly improve blood sugar stability and reduce high blood sugar episodes without increasing the risk of dangerous low blood sugar. This switch should be considered when current therapy fails, keeping in mind that mild stomach issues may occur but are generally manageable.

Exercise interventions in T2D are mediated by molecular mechanisms including exerkines (e.g., GDF15, Irisin), b-cell function enhancement, and epigenetic changes.

Exercise works by triggering specific biological signals (like exerkines) that improve how your body handles sugar and protects your pancreas.

GLP-1 receptor agonists provide neuroprotective benefits, including potential improvement in cognitive function and reduction in neurodegenerative disease progression (Alzheimer's and Parkinson's).

GLP-1 RAs are being studied for their potential to protect the brain in Alzheimer's and Parkinson's disease. They may reduce inflammation and oxidative stress in the brain. While not yet a standard treatment for these conditions, the biological plausibility is strong, and patients with these diseases should discuss the potential benefits with their neurologist.

Indiscriminate use of Semaglutide for weight loss without medical supervision poses significant health risks, including gastrointestinal distress, hypoglycemia, and potential renal or pancreatic complications.

Do not use Semaglutide for weight loss without a doctor's prescription and monitoring. The risks, including severe stomach issues and low blood sugar, are significant when used indiscriminately. Sustainable weight loss requires lifestyle changes, not just medication.

GIP receptor antagonism promotes weight loss and protects against diet-induced obesity, potentially by enhancing leptin sensitivity in the hypothalamus and reducing lipid storage in adipose tissue.

Research indicates that blocking the GIP receptor (antagonism) can also lead to weight loss, possibly by improving how your body responds to leptin and reducing fat storage. This is an emerging area of treatment, with some drugs in clinical trials combining GIP antagonism with GLP-1 agonism for enhanced effects.

Higher starch intake is associated with lower levels of specific plasma proteins (adrenomedullin, IL1ra, FABP4, leptin, CCL20) that are themselves positively associated with increased CVD and mortality risk.

This finding suggests that moderate starch intake may help regulate inflammatory and adiposity-related proteins. However, since the association weakened after adjusting for BMI, maintaining a healthy weight is likely the primary driver of these benefits.

Off-label prescribing of semaglutide (Ozempic) for weight loss causes significant supply shortages for patients with type 2 diabetes who require the medication for its FDA-approved indication.

If you are considering Ozempic for weight loss, understand that it is a serious medication, not a cosmetic shortcut. It works by mimicking hormones that regulate hunger, but stopping it often leads to significant weight regain. Be aware that high demand for off-label use has caused shortages for people who need it for diabetes, so discuss ethical access and long-term sustainability with your doctor before starting.

High-intensity acute exercise suppresses hunger and food intake, but this suppression is not associated with a decrease in total ghrelin concentration.

If you are tracking hormones to understand your appetite, note that total ghrelin levels may not change during high-intensity exercise even if you feel less hungry. The active form, acyl ghrelin, is likely the key driver of this suppression.

GLP-1 receptor agonist therapy improves tear production and tear film stability in patients with type 2 diabetes compared to non-GLP-1 RA therapies.

If you have Type 2 Diabetes and are considering or using GLP-1 RAs (like semaglutide or dulaglutide), this research suggests these medications might actually help keep your eyes moist and stable compared to other diabetes drugs. While this doesn't replace standard dry eye treatments, it is a potential benefit to discuss with your doctor, especially if you suffer from dry eye symptoms.

Network pharmacology analysis suggests that the synergistic mechanism of combined exercise and medication involves the IL1B-STAT3 inflammatory axis and SIRT1/CD36 lipid metabolism network.

This is a mechanistic hypothesis. It suggests that combining exercise and medication may work by reducing inflammation (IL1B-STAT3) and improving lipid metabolism (SIRT1/CD36).

Low-carbohydrate diets (≤60 g/d) do not have a significant adverse effect on serum lipid profiles, fasting serum glucose, fasting serum insulin levels, or blood pressure compared to higher-carbohydrate diets.

You can use a low-carbohydrate diet without fearing immediate harm to your heart health, blood sugar control, or blood pressure based on this review. The safety profile appears comparable to higher-carb diets for these specific markers.

Saturated fat consumption has no independent association with incident diabetes in prospective cohort studies, despite mixed results in short-term randomized trials.

You do not need to fear saturated fat as a direct cause of diabetes. Focus on maintaining a healthy weight and eating a balanced diet. The type of fat matters less for diabetes risk than the overall quality of your diet and your body weight.

Phentermine and Phentermine/Topiramate are associated with a higher incidence of acute kidney injury (AKI) and kidney injury events compared to other anti-obesity medications, and require dose adjustments in CKD stages 3+.

Avoid stimulant-based weight loss drugs like phentermine if you have CKD, especially stage 3 or higher. They carry a higher risk of kidney injury and require dose adjustments. GLP-1 medications are a safer and more effective option for protecting your kidneys while losing weight.

Dual GLP-1/glucagon agonists (e.g., cotadutide, pemvidutide) provide greater reductions in liver fat and fibrosis markers than GLP-1 mono-agonists, likely due to glucagon-mediated mitochondrial turnover and glycogenolysis.

If GLP-1 mono-agonists (like semaglutide) are not enough, dual agonists (like cotadutide or pemvidutide) may offer greater liver fat reduction and fibrosis improvement. However, these drugs are more complex and may cause more side effects. They are currently in clinical trials and not yet standard care. Discuss with your hepatologist if you are a candidate for these newer agents, especially if you have significant liver fat but stable diabetes.

Acute ingestion of alcohol (1.09 g ethanol/kg lean mass) immediately after heavy resistance exercise significantly attenuates post-exercise mTOR and S6K1 phosphorylation in resistance-trained men, thereby blunting the signaling pathway responsible for muscle protein synthesis.

If you train hard, avoid drinking alcohol for at least 3 hours after your workout. This study shows that alcohol blunts the specific cellular signals (mTOR) your body needs to build muscle. If you must drink, wait until several hours post-exercise to minimize the interference with your training adaptations.

Semaglutide use is associated with a high incidence of gastrointestinal adverse events, including nausea, vomiting, diarrhea, and constipation, with signal strength varying by clinical priority and time-to-onset.

If you are taking semaglutide, expect gastrointestinal side effects like nausea, vomiting, or diarrhea, especially when starting or increasing the dose. These are common and often decrease over time. Discuss starting with a lower dose and titrating slowly with your provider to improve tolerance. Ensure you stay hydrated and eat smaller, bland meals if symptoms occur.

Gut microbiota dysbiosis in obesity contributes to low-grade inflammation and increased fat storage through mechanisms including increased gut permeability (leaky gut), systemic lipopolysaccharide (LPS) circulation, and altered signaling of satiety hormones (GLP-1, PYY, ghrelin) via the gut-brain axis.

Focus on dietary fiber and diverse plant foods to support a healthy gut microbiome, which may help regulate satiety hormones and reduce inflammation. While not a standalone cure, this biological lever supports overall metabolic health.

Aging significantly reduces sympathetic nervous system (SNS) drive to brown adipose tissue (BAT), leading to diminished metabolic BAT activity, whereas obesity alone does not impair SNS drive or metabolic activity.

If you are older, your body's natural signal to burn fat via brown fat (triggered by cold) is weaker than it was when you were young. This is not because you are obese, but because of age-related neural changes. Standard cold exposure might be less effective for you than for a young person, suggesting that interventions specifically targeting sympathetic nerve activity might be necessary to activate your brown fat.

The presence of metabolic syndrome significantly increases the risk of ischemic heart disease in type 2 diabetes patients, whereas individual metabolic risk factors do not significantly increase cardiovascular risk in the absence of the syndrome.

If you have Type 2 Diabetes, managing your blood pressure, cholesterol, and weight individually is not enough. You must address the cluster of metabolic issues (Metabolic Syndrome) as a whole, because the combination of these factors drastically increases your risk of heart disease, whereas treating them one by one may not reduce that risk effectively.

Ten consecutive nights of sleeping in moderate hypoxia (approx. 2,400m elevation, 15% O2) improves whole-body insulin sensitivity in obese humans, primarily through enhanced insulin-independent glucose uptake mechanisms.

For obese individuals with insulin resistance, sleeping in a controlled moderate hypoxic environment (simulating ~2,400m altitude) for 10 nights may significantly improve how their bodies handle glucose. This effect appears to work by boosting insulin-independent glucose uptake in muscles rather than changing insulin signaling itself. While not a substitute for diet and exercise, it represents a potential therapeutic adjunct for prediabetes.

Six months of once-weekly GLP-1 analogue (semaglutide) therapy restores natural killer (NK) cell effector function (cytotoxicity and cytokine production) in people with obesity, independent of weight loss.

For people with obesity, GLP-1 therapy (like semaglutide) may strengthen the immune system's ability to fight viruses and cancer, independent of how much weight is lost. This suggests benefits beyond just metabolic health.

GLP-1 therapy restores NK cell metabolism by upregulating the CD98-mTOR-glycolysis axis, which is critical for NK cell cytokine production.

GLP-1 therapy helps fix the 'metabolic engine' of immune cells (NK cells) in obese individuals, allowing them to produce necessary defense chemicals (cytokines) more effectively.